GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-03-27|

BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)

by GeneOnline
Share To

SHANGHAI, March 28, 2023 /PRNewswire/ — BJ Bioscience, Inc. BJ Bioscience, a biotech company focusing on discovery and development of novel biologics for cancer immunotherapy, today announced that it entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). The collaboration will allow for the evaluation of safety and efficacy of BJ-001, a tumor-targeting IL-15 fusion protein, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in an ongoing Phase 1 clinical trial. 

BJ Bioscience will evaluate BJ-001 plus KEYTRUDA as part of the company’s ongoing trial in patients with locally advanced/metastatic solid tumors. In this trial, BJ-001 is studied as monotherapy or in combination with KEYTRUDA, for safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity.

In monotherapy dose escalation cohorts, BJ-001 has demonstrated tolerable safety profiles, favorable PK/PD profiles, and encouraging preliminary efficacy results. 

"BJ Bioscience is excited to collaborate with MSD, one of the world’s leading multinational pharmaceutical companies," said Joe Zhang, MD, PhD, cofounder and CEO of BJ Bioscience. "Many consider KEYTRUDA to be one of the gold-standard medicines in the cancer immunotherapy arena. We believe BJ-001 may be a promising addition to this area. Our preclinical studies demonstrated that the combination of BJ-001 and an anti-PD-1 antibody was well-tolerated and showed promising early antitumor activity compared to either drug alone as monotherapy. With its tumor-targeting properties, we’re looking forward to evaluating BJ-001 in combination with KEYTRUDA as a potential new treatment option to benefit more cancer patients. This investigational combination is a key component of our BJ-001 development program."

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About BJ-001
BJ-001 is a tumor-targeting IL-15 fusion protein, designed to expand and activate cancer-fighting natural killer (NK) cells and CD8+ T cells, and to have selected distribution in tumors with high integrin-expression. Preclinical data have demonstrated the ability of BJ-001 to accumulate in integrin-expressing tumors. Clinical data to date have shown Best-in-Class properties of BJ-001, including tolerable safety, dose-dependent and encouraging magnitude of stimulation and expansion of NK cells and CD8+ T cells with no impact on immunosuppressive regulatory T cells.

About BJ Bioscience, Inc.

BJ Bioscience Inc. is a clinical stage biotech company creating next generation of immunotherapies for cancer, inflammation and autoimmunity using its trade secret protected antibody discovery and screening technology and SIB® bispecific antibody platform.  BJ Bioscience’s lead asset, BJ-001, is in Phase 1 clinical studies in the US and China. For more information, please visit the BJ Bioscience website: www.bjbioscience.com.

Contacts:

Media
[email protected]

Investors
[email protected]

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top